Rivaroxaban and its Effect on International Normalised Ratio-A Prospective Study of 28 Hip and Knee Arthroplasty Patients

C. Yeo, V. Eranki, A. Pillai, G. Morrison
{"title":"Rivaroxaban and its Effect on International Normalised Ratio-A Prospective Study of 28 Hip and Knee Arthroplasty Patients","authors":"C. Yeo, V. Eranki, A. Pillai, G. Morrison","doi":"10.3844/AMJSP.2012.126.129","DOIUrl":null,"url":null,"abstract":"Problem statement: Rivaroxaban is an orally active, competitively reversible antagonist of activated factor Xa. The purpose of this study is to comment on Riveroxaban’s effect on INR. Approach: At the Queen Elizabeth Hospital, all patients undergoing elective anthroplasty were anticoagulated with 10mg of Rivaroxaban. All patients had INR measurements for 3 days post operatively. Further 16 patients had weekly INR follow follow up for the reminder of their therapy. Measurements between 0.2-1.2 were classified normal, 1.3-1.4 elevated and INR>1.4 high. Results: On day 1 after Rivaroxaban was commenced, 67.9% of patients recorded high INR value of >1.4 while 7.1% of patients had normal value of INR value (0.8-1.2). However, the number of patient with normal value of INR increased over next 2 days. On the third day after Rivaroxaban was commenced, 35.7% of the patients recorded a normal INR value while 32.1% of the studied patients had recorded mild elevated INR value. 32.1% of the studied patients had high INR value. All patients had an INR greater than 1.1. In the first 3 days, the maximum INR reached was 3.1. In patients who. All patients with a normal INR on day 1 remined normal throughout their course. 4 patients with an elevated INR on day 1 normalised by day 3. 8 patients had an INR trend upwards from day 1-2. 3 patients had a higher INR at day 3 compared to day 1. Of the 16 pateints followed up till the end of their therapy, 68.8% patients had a normal, 18.8% elevated and 12.5% patients had a high INR. Conclusion: Rivaroxaban has been proven as an effective alternate to existing anticoagulats in tehrms of patient compliance, rates of thrombus and bleeding risks. This study successfully demonstrates that Rivaroxaban leads to a trancient increase in INR in the majority of pateints in the first 72 h. Nil litrature exists on the effect of Rivaroxaban on prothrombin time and appropriate reversal and mangemetn of pateints who require further surgical intervention. Further research is required into invistigating the cause and effect of this increase.","PeriodicalId":89887,"journal":{"name":"American medical journal","volume":"3 1","pages":"126-129"},"PeriodicalIF":0.0000,"publicationDate":"2012-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3844/AMJSP.2012.126.129","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3844/AMJSP.2012.126.129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Problem statement: Rivaroxaban is an orally active, competitively reversible antagonist of activated factor Xa. The purpose of this study is to comment on Riveroxaban’s effect on INR. Approach: At the Queen Elizabeth Hospital, all patients undergoing elective anthroplasty were anticoagulated with 10mg of Rivaroxaban. All patients had INR measurements for 3 days post operatively. Further 16 patients had weekly INR follow follow up for the reminder of their therapy. Measurements between 0.2-1.2 were classified normal, 1.3-1.4 elevated and INR>1.4 high. Results: On day 1 after Rivaroxaban was commenced, 67.9% of patients recorded high INR value of >1.4 while 7.1% of patients had normal value of INR value (0.8-1.2). However, the number of patient with normal value of INR increased over next 2 days. On the third day after Rivaroxaban was commenced, 35.7% of the patients recorded a normal INR value while 32.1% of the studied patients had recorded mild elevated INR value. 32.1% of the studied patients had high INR value. All patients had an INR greater than 1.1. In the first 3 days, the maximum INR reached was 3.1. In patients who. All patients with a normal INR on day 1 remined normal throughout their course. 4 patients with an elevated INR on day 1 normalised by day 3. 8 patients had an INR trend upwards from day 1-2. 3 patients had a higher INR at day 3 compared to day 1. Of the 16 pateints followed up till the end of their therapy, 68.8% patients had a normal, 18.8% elevated and 12.5% patients had a high INR. Conclusion: Rivaroxaban has been proven as an effective alternate to existing anticoagulats in tehrms of patient compliance, rates of thrombus and bleeding risks. This study successfully demonstrates that Rivaroxaban leads to a trancient increase in INR in the majority of pateints in the first 72 h. Nil litrature exists on the effect of Rivaroxaban on prothrombin time and appropriate reversal and mangemetn of pateints who require further surgical intervention. Further research is required into invistigating the cause and effect of this increase.
利伐沙班及其对28例髋关节置换术患者国际标准化比率的影响
问题说明:利伐沙班是一种口服活性的、竞争性可逆的活化因子Xa拮抗剂。本研究的目的是评价Riveroxaban对INR的影响。方法:在伊丽莎白女王医院,所有接受择期人体成形术的患者使用10mg利伐沙班进行抗凝治疗。所有患者术后3天测量INR。另有16例患者每周进行INR随访,以提醒他们的治疗。测量值在0.2-1.2之间归类为正常,1.3-1.4升高,INR>1.4高。结果:利伐沙班开始治疗后第1天,67.9%的患者INR值高,为bb0 1.4, 7.1%的患者INR值正常(0.8-1.2)。然而,在接下来的2天内,INR值正常的患者数量有所增加。在利伐沙班开始治疗的第3天,35.7%的患者记录到INR值正常,而32.1%的患者记录到INR值轻度升高。32.1%的患者INR值较高。所有患者的INR均大于1.1。前3天,最高INR为3.1。对于那些。所有第1天INR正常的患者在整个疗程中都保持正常。第1天INR升高的4例患者在第3天恢复正常。8例患者INR在第1-2天呈上升趋势。3例患者在第3天的INR高于第1天。16例患者随访至治疗结束,68.8%患者INR正常,18.8%患者INR升高,12.5%患者INR高。结论:在患者依从性、血栓发生率和出血风险方面,利伐沙班已被证明是现有抗凝药物的有效替代。本研究成功地证明了利伐沙班导致大多数患者在最初72小时内短暂的INR升高。没有关于利伐沙班对凝血酶原时间的影响以及需要进一步手术干预的患者的适当逆转和管理的文献。需要进一步的研究来调查这一增长的原因和影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书